头孢他啶治疗严重细菌感染的开放性研究。

An open study of ceftazidime in the treatment of serious bacterial infection.

作者信息

Allan S G, Glover S C, Smith C C, Hadley K M, Reid T M, Han K, Murdoch J M, Ingram P M

出版信息

J Antimicrob Chemother. 1983 Sep;12(3):219-27. doi: 10.1093/jac/12.3.219.

DOI:10.1093/jac/12.3.219

Abstract

Ceftazidime, a new parenteral cephalosporin, was given by intravenous bolus injection to 50 patients admitted to hospital with a variety of serious infections. These included septicaemia, bronchopulmonary, urinary, gastro-intestinal and soft tissue infections. The drug proved to be effective against a wide range of organisms, notably opportunistic Pseudomonas aeruginosa infections. In the 32 patients with positive cultures there was a cure rate of 85%. All Ps. aeruginosa infections were eradicated, but two relapsed post treatment in patients with recurrent urinary infections related to indwelling catheters. The drug was well tolerated and no serious side effects occurred. Two patients with salmonella septicaemia relapsed after an initial clinical response, and one of these died.

摘要

头孢他啶是一种新型胃肠外头孢菌素，对50例因各种严重感染入院的患者进行了静脉推注给药。这些感染包括败血症、支气管肺部感染、泌尿系统感染、胃肠道感染和软组织感染。该药物对多种微生物有效，尤其是对机会性铜绿假单胞菌感染有效。在32例培养结果呈阳性的患者中，治愈率为85%。所有铜绿假单胞菌感染均被根除，但2例与留置导尿管相关的复发性泌尿系统感染患者在治疗后复发。该药物耐受性良好，未出现严重副作用。2例沙门氏菌败血症患者在最初出现临床反应后复发，其中1例死亡。